Seascape Clinical articles

The Holiday season often brings mixed feelings for many. While it can be a time of relaxation with friends and family for some, for others, preparing for this time means ensuring business continuity despite a typical slow down. This can be a source of undue stress if it is not suitably planned for.

Revisiting the “why” behind decision making can be a helpful exercise in all aspects of business. This is no less true for clinical operations executives when it comes to the clinical trial systems they employ to facilitate their teams’ work.

The technology that supports clinical trial systems has evolved steadily over the past several decades, yet the ultimate goal of streamlining workflows and improving output continues to be a challenge to differe

When promising drug candidates are identified for further investigation in clinical trials, sponsor companies are usually optimistic about outcomes.

But there are times, when after years of sunk effort and resources, clinical trials fail to bring a viable drug to market.  Frequently, a drug fails for safety or efficacy reasons that are beyond a sponsor’s control.  However, to some degree, sponsors can control:

• The speed

In the developed world, 1 in 4 people die from cancer or cancer-related disease, and cancer accounts for 13% of deaths globally.

Oncology is the fastest growing therapeutic area by revenue and number of clinical trials. There’s been a huge emphasis on developing new treatments to improve survival in patients with cancer, but these trials have become a costly undertaking for sponsor companies.

In general, clinical trials can be slow to complete and expens

Annual planning is an opportunity to fix this long-standing clinical operations issue

At the beginning of many pharma companies’ financial year, an annual planning process occurs.  This presents an opportunity for stakeholders to align on short-, mid-, and long-term goals.

Clinical stage pharma companies focus on clinical-trial related goals.  These include completing ongoing clinical trials and initiating new ones, in the context of the compan